JP2008534627A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008534627A5 JP2008534627A5 JP2008504532A JP2008504532A JP2008534627A5 JP 2008534627 A5 JP2008534627 A5 JP 2008534627A5 JP 2008504532 A JP2008504532 A JP 2008504532A JP 2008504532 A JP2008504532 A JP 2008504532A JP 2008534627 A5 JP2008534627 A5 JP 2008534627A5
- Authority
- JP
- Japan
- Prior art keywords
- amylin
- seq
- disorder
- disease
- agonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000036849 Islet amyloid polypeptide Human genes 0.000 claims 59
- 108010041872 Islet amyloid polypeptide Proteins 0.000 claims 59
- 201000010099 disease Diseases 0.000 claims 27
- 239000000556 agonist Substances 0.000 claims 17
- 206010057666 Anxiety disease Diseases 0.000 claims 11
- 206010037175 Psychiatric disease Diseases 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 201000000980 schizophrenia Diseases 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 206010061284 Mental disease Diseases 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- 102400000113 Calcitonin Human genes 0.000 claims 3
- 108060001064 Calcitonin Proteins 0.000 claims 3
- 229960004015 Calcitonin Drugs 0.000 claims 3
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical group N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims 3
- 201000008895 mood disease Diseases 0.000 claims 3
- 201000008430 obsessive-compulsive disease Diseases 0.000 claims 3
- 206010012335 Dependence Diseases 0.000 claims 2
- 206010072387 Substance-induced mood disease Diseases 0.000 claims 2
- 231100000395 Substance-induced mood disorder Toxicity 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 201000009031 substance-related disease Diseases 0.000 claims 2
- 229940079593 drugs Drugs 0.000 claims 1
- 201000006152 substance dependence Diseases 0.000 claims 1
Claims (24)
医薬が該疾患または障害を治療するために有効な量で投与され、アミリンアゴニストがカルシトニンではない該アミリン、アミリンアゴニスト、アミリンアナログまたはアミリン誘導体。 SEQ ID NO: 3, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 67, SEQ ID NO: 80, SEQ ID NO: 81 for treating mood disorders, anxiety disorders or mental disorders or disorders that are schizophrenia An amylin, amylin agonist, amylin analog or amylin derivative selected from the group consisting of the compounds set forth in SEQ ID NO: 82 and SEQ ID NO: 83,
The amylin, amylin agonist, amylin analog or amylin derivative, wherein a medicament is administered in an amount effective to treat the disease or disorder and the amylin agonist is not calcitonin.
医薬が該疾患または障害を治療するために有効な量で投与され、アミリンアゴニストがカルシトニンではない該医薬組成物。 SEQ ID NO: 3, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 67, SEQ ID NO: 80, SEQ ID NO: 81 for treating mood disorders, anxiety disorders or mental disorders or disorders that are schizophrenia A pharmaceutical composition comprising amylin, amylin agonist, amylin analog or amylin derivative selected from the group consisting of the compounds of SEQ ID NO: 82 and SEQ ID NO: 83,
The pharmaceutical composition, wherein the medicament is administered in an amount effective to treat the disease or disorder and the amylin agonist is not calcitonin.
医薬が該疾患または障害を治療するために有効な量で投与され、アミリンアゴニストがカルシトニンではないことを特徴とする該使用。 SEQ ID NO: 3, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 67, SEQ ID NO: 80, for the manufacture of a medicament for the treatment of mood disorders, anxiety disorders or psychiatric diseases or disorders that are schizophrenia Use of an amylin, amylin agonist, amylin analog or amylin derivative selected from the group consisting of the compounds set forth in SEQ ID NO: 81, SEQ ID NO: 82 and SEQ ID NO: 83,
The use wherein the medicament is administered in an amount effective to treat the disease or disorder and the amylin agonist is not calcitonin.
医薬が該障害を治療するために有効な量で投与され、物質関連障害が、物質依存、物質嗜癖、物質誘導不安障害および物質誘導気分障害よりなる群から選択される該使用。 SEQ ID NO: 3, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 67, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 82 and SEQ ID NO: 83 for the manufacture of a medicament for treating psychiatric disorders Use of an amylin, amylin agonist, amylin analog or amylin derivative selected from the group consisting of the compounds described in
The use wherein the medicament is administered in an amount effective to treat the disorder and the substance related disorder is selected from the group consisting of substance dependence, substance addiction, substance induced anxiety disorder and substance induced mood disorder.
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66733505P | 2005-03-31 | 2005-03-31 | |
| US66668105P | 2005-03-31 | 2005-03-31 | |
| US60/667,335 | 2005-03-31 | ||
| US60/666,681 | 2005-03-31 | ||
| US67544105P | 2005-04-28 | 2005-04-28 | |
| US60/675,441 | 2005-04-28 | ||
| US76058306P | 2006-01-20 | 2006-01-20 | |
| US60/760,583 | 2006-01-20 | ||
| PCT/US2006/012601 WO2006105527A2 (en) | 2005-03-31 | 2006-03-31 | Amylin and amylin agonists for treating psychiatric diseases and disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008534627A JP2008534627A (en) | 2008-08-28 |
| JP2008534627A5 true JP2008534627A5 (en) | 2009-05-21 |
| JP5114381B2 JP5114381B2 (en) | 2013-01-09 |
Family
ID=37054153
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008504396A Expired - Fee Related JP5415067B2 (en) | 2005-03-31 | 2006-03-31 | Compositions and methods for the control, prevention and treatment of obesity and eating disorders |
| JP2008504532A Expired - Fee Related JP5114381B2 (en) | 2005-03-31 | 2006-03-31 | Amylin and amylin agonists for the treatment of psychiatric disorders and disorders |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008504396A Expired - Fee Related JP5415067B2 (en) | 2005-03-31 | 2006-03-31 | Compositions and methods for the control, prevention and treatment of obesity and eating disorders |
Country Status (17)
| Country | Link |
|---|---|
| US (7) | US7879794B2 (en) |
| EP (5) | EP1888094B1 (en) |
| JP (2) | JP5415067B2 (en) |
| KR (3) | KR20080003849A (en) |
| CN (3) | CN102343084A (en) |
| AT (2) | ATE439140T1 (en) |
| AU (2) | AU2006230420B2 (en) |
| BR (2) | BRPI0609595A8 (en) |
| CA (2) | CA2602261A1 (en) |
| DE (2) | DE602006008456D1 (en) |
| DK (1) | DK1888094T3 (en) |
| EA (1) | EA013121B1 (en) |
| ES (1) | ES2330671T3 (en) |
| IL (1) | IL186200A (en) |
| MX (2) | MX2007012236A (en) |
| NZ (3) | NZ561936A (en) |
| WO (2) | WO2006105345A2 (en) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
| DE602005021858D1 (en) * | 2004-02-11 | 2010-07-29 | Amylin Pharmaceuticals Inc | PEPTIDES OF THE AMYLIN FAMILY, PROCESS FOR THEIR PREPARATION AND USE |
| WO2006105345A2 (en) | 2005-03-31 | 2006-10-05 | Amylin Pharmaceuticals, Inc. | Compositions and methods for the control, prevention, and treatment of obesity and eating disorders |
| WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
| US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
| WO2007014051A2 (en) * | 2005-07-22 | 2007-02-01 | Amylin Pharmaceuticals, Inc. | Use of amylin and amylin agonists as cardioprotective or myoprotective agents |
| CN101400698A (en) | 2006-03-15 | 2009-04-01 | 诺沃-诺迪斯克有限公司 | Amylin derivatives |
| US20090181890A1 (en) * | 2006-03-31 | 2009-07-16 | Amylin Pharmaceuticals , Inc. | Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders |
| MX2008012666A (en) * | 2006-03-31 | 2008-10-13 | Amylin Pharmaceuticals Inc | Amylin and amylin agonists for treating psychiatric diseases and disorders. |
| MX2008014870A (en) | 2006-05-30 | 2009-02-12 | Intarcia Therapeutics Inc | Two-piece, internal-channel osmotic delivery system flow modulator. |
| EP2363112B8 (en) | 2006-08-09 | 2018-11-21 | Intarcia Therapeutics, Inc. | Osmotic delivery systems and piston assemblies |
| US8309522B2 (en) | 2007-02-05 | 2012-11-13 | Amylin Pharmaceuticals, Llc | Neuromedin and FN-38 peptides for treating psychiatric diseases |
| EP2157967B1 (en) | 2007-04-23 | 2013-01-16 | Intarcia Therapeutics, Inc | Suspension formulations of insulinotropic peptides and uses thereof |
| US8343140B2 (en) | 2008-02-13 | 2013-01-01 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
| EP2293811A1 (en) * | 2008-06-25 | 2011-03-16 | Novo Nordisk A/S | Derivatised hybrid peptides of amylin and salmon calcitonin |
| WO2010046357A1 (en) * | 2008-10-21 | 2010-04-29 | Novo Nordisk A/S | Amylin derivatives |
| SI2373681T1 (en) | 2008-12-10 | 2017-05-31 | Glaxosmithkline Llc Corporation Service Company | Pharmaceutical compositions of albiglutide |
| DK2389388T3 (en) * | 2009-01-22 | 2017-05-01 | Keybioscience Ag | TREATMENT FOR Obesity |
| EP2416797A4 (en) * | 2009-04-10 | 2013-04-24 | Amylin Pharmaceuticals Llc | Amylin agonist compounds for estrogen-deficient mammals |
| EP2421524B1 (en) | 2009-04-20 | 2018-08-08 | Elcelyx Therapeutics, Inc. | Chemosensory receptor ligand-based therapies |
| US8828953B2 (en) * | 2009-04-20 | 2014-09-09 | NaZura BioHealth, Inc. | Chemosensory receptor ligand-based therapies |
| US9901551B2 (en) | 2009-04-20 | 2018-02-27 | Ambra Bioscience Llc | Chemosensory receptor ligand-based therapies |
| AU2010298733B2 (en) | 2009-09-28 | 2014-10-09 | Intarcia Therapeutics, Inc. | Rapid establishment and/or termination of substantial steady-state drug delivery |
| US8476227B2 (en) | 2010-01-22 | 2013-07-02 | Ethicon Endo-Surgery, Inc. | Methods of activating a melanocortin-4 receptor pathway in obese subjects |
| US9044606B2 (en) | 2010-01-22 | 2015-06-02 | Ethicon Endo-Surgery, Inc. | Methods and devices for activating brown adipose tissue using electrical energy |
| JP2013525491A (en) | 2010-05-04 | 2013-06-20 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection |
| US20110317346A1 (en) | 2010-06-28 | 2011-12-29 | Zte Corporation | Totally-enclosed integrative access system and power consumption reduction method thereof |
| AU2011317140A1 (en) | 2010-10-19 | 2013-05-30 | Elcelyx Therapeutics, Inc. | Chemosensory receptor ligand-based therapies |
| HUE051738T2 (en) | 2011-01-07 | 2021-03-29 | Anji Pharma Us Llc | Chemosensory receptor ligand-based therapies |
| WO2013103384A1 (en) | 2012-01-06 | 2013-07-11 | Elcelyx Therapeutics, Inc. | Biguanide compositions and methods of treating metabolic disorders |
| US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
| CN109306015B (en) * | 2011-06-17 | 2022-04-26 | 韩美科学株式会社 | Conjugates comprising oxyntomodulin and immunoglobulin fragment and uses thereof |
| JP6025871B2 (en) * | 2012-01-26 | 2016-11-16 | クリストファー ジェイ． ソアレス | Peptide antagonists of the calcitonin CGRP family of peptide hormones and uses thereof |
| WO2013158928A2 (en) | 2012-04-18 | 2013-10-24 | Elcelyx Therapeutics, Inc. | Chemosensory receptor ligand-based therapies |
| BR102013017626A2 (en) * | 2013-06-14 | 2015-02-10 | Univ Rio De Janeiro | NON-AGGLOMANTANT BIOCONJUGATES WITH POLYETHYLENEGLYCOL, NON-AGGLOMANTANT BIOCONJUGATES WITH POLYETHYLENEGLYCOL, PHARMACEUTICAL COMPOSITIONS OF LOW TOXICITY, ADJUSTING OR PREVENTION OF THE PREVENTION OF PREVENTION MEASUREMENT |
| EP3027644B1 (en) * | 2013-07-30 | 2019-08-21 | Christopher J. Soares | Cgrp agonist peptides |
| AR097701A1 (en) * | 2013-09-19 | 2016-04-13 | Zealand Pharma As | AMILINE ANALOGS |
| US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
| US10080884B2 (en) | 2014-12-29 | 2018-09-25 | Ethicon Llc | Methods and devices for activating brown adipose tissue using electrical energy |
| US10092738B2 (en) | 2014-12-29 | 2018-10-09 | Ethicon Llc | Methods and devices for inhibiting nerves when activating brown adipose tissue |
| EP3302354B1 (en) | 2015-06-03 | 2023-10-04 | i2o Therapeutics, Inc. | Implant placement systems |
| RU2760007C2 (en) | 2016-05-16 | 2021-11-22 | Интарсия Терапьютикс, Инк. | Polypeptides selective to glucagon receptors and their application methods |
| USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
| USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
| US11390654B2 (en) | 2016-09-02 | 2022-07-19 | Christopher Joseph Soares | Use of CGRP receptor antagonists in neuroprotection and neurological disorders |
| IL307966A (en) | 2017-01-03 | 2023-12-01 | Intarcia Therapeutics Inc | Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug |
| EP3568411B1 (en) * | 2017-01-13 | 2024-03-06 | Pietro P. Sanna | Methods and compositions for treating hpa hyperactivity |
| EP3628233B1 (en) * | 2018-09-28 | 2021-06-02 | Siemens Healthcare GmbH | Method and system for providing a dose reference value for a patient |
| US11443843B2 (en) | 2019-01-04 | 2022-09-13 | International Business Machines Corporation | Personal customized guidance for treating patients |
| CN111700904A (en) * | 2020-07-31 | 2020-09-25 | 江南大学 | Antidepressant method for releasing short-chain fatty acid at fixed point by using acylated starch |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3065460D1 (en) | 1979-07-28 | 1983-12-08 | Beecham Group Plc | Benzocycloheptapyrrolealkanoic acids and their derivatives, processes for their preparation and pharmaceutical compositions containing them |
| US4401593A (en) | 1982-02-12 | 1983-08-30 | Armour Pharmaceutical Company | Glycine - 8 calcitonin |
| US4397780A (en) | 1982-02-12 | 1983-08-09 | Armour Pharmaceutical Company | Leucine22 -calcitonin |
| US4414149A (en) | 1983-03-04 | 1983-11-08 | Armour Pharmaceutical Company | Glycine8 -D-arginine24 calcitonin |
| US4497731A (en) | 1983-04-04 | 1985-02-05 | Armour Pharmaceutical Company | Glycine 8-des-tyrosine 22 calcitonin |
| US4495097A (en) | 1983-04-04 | 1985-01-22 | Armour Pharmaceutical Company | Des-serine2 -glycine8 calcitonin |
| US4572208A (en) | 1983-06-29 | 1986-02-25 | Utah Medical Products, Inc. | Metabolic gas monitoring apparatus and method |
| US4597900A (en) | 1983-08-22 | 1986-07-01 | Armour Pharmaceutical Co. | Des2 -glycine8 -des22 -calcitonin |
| US4537716A (en) | 1983-12-05 | 1985-08-27 | Armour Pharmaceutical Co. | Des-serine2 or des-glycine2 -leucine22 calcitonin |
| FI78231C (en) | 1984-11-21 | 1989-07-10 | Instrumentarium Oy | Measuring device for metabolic quantities connectable to a respirator |
| US4604238A (en) | 1984-12-10 | 1986-08-05 | Armour Pharmaceutical Company | Analogs of calcitonin |
| US4606856A (en) | 1985-03-18 | 1986-08-19 | Seyler Jay K | [Des-1-amino, 8-glycine]calcitonin |
| US4652627A (en) | 1985-08-16 | 1987-03-24 | Kempe Tomas G | Calcitonin analogs with C-terminal D-amino acid substituents |
| US4697002A (en) | 1985-12-23 | 1987-09-29 | Kempe Tomas G | Calcitonin gene related peptide analogs with amino acid subdstituents at the penultimate position 36 |
| US4687839A (en) | 1985-12-23 | 1987-08-18 | Kempe Tomas G | Calcitonin gene related peptide analogs with C-terminal D-amino acid substituents |
| GB8709871D0 (en) | 1987-04-27 | 1987-06-03 | Turner R C | Peptides |
| US5175145A (en) * | 1988-08-26 | 1992-12-29 | Amylin Pharmaceuticals, Inc. | Treatment of diabetes mellitus with amylin agonists |
| ATE135370T1 (en) | 1988-12-22 | 1996-03-15 | Kirin Amgen Inc | CHEMICALLY MODIFIED GRANULOCYTE COLONY EXCITING FACTOR |
| US5405831A (en) | 1989-07-08 | 1995-04-11 | Amylin Pharmaceuticals, Inc. | Treatment of bone disorders |
| US5264372A (en) | 1991-03-15 | 1993-11-23 | Amylin Pharmaceuticals, Inc. | Receptor-based screening methods for amylin agonists and antagonists |
| US5234906A (en) * | 1991-01-10 | 1993-08-10 | Amylin Pharmaceuticals, Inc. | Hyperglycemic compositions |
| HU222249B1 (en) | 1991-03-08 | 2003-05-28 | Amylin Pharmaceuticals Inc. | Process for producing amyline antagonistic peptide derivatives and pharmaceutical preparatives containing them |
| EP0567626B1 (en) * | 1991-11-19 | 2001-09-19 | Amylin Pharmaceuticals, Inc. | Amylin agonist peptides and uses therefor |
| US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
| US6001364A (en) | 1993-05-05 | 1999-12-14 | Gryphon Sciences | Hetero-polyoxime compounds and their preparation by parallel assembly |
| US6174530B1 (en) | 1993-05-05 | 2001-01-16 | Gryphon Sciences | Homogeneous polyoxime compositions and their preparation by parallel assembly |
| US5589356A (en) | 1993-06-21 | 1996-12-31 | Vanderbilt University | Litigation of sidechain unprotected peptides via a masked glycoaldehyde ester and O,N-acyl rearrangement |
| DE69426304T2 (en) | 1993-09-07 | 2001-03-15 | Amylin Pharmaceuticals, Inc. | METHODS FOR THE REGULATION OF STOMACH AND BOWEL MOTILITY |
| US5766627A (en) | 1993-11-16 | 1998-06-16 | Depotech | Multivescular liposomes with controlled release of encapsulated biologically active substances |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US6184344B1 (en) | 1995-05-04 | 2001-02-06 | The Scripps Research Institute | Synthesis of proteins by native chemical ligation |
| US5739106A (en) * | 1995-06-07 | 1998-04-14 | Rink; Timothy J. | Appetite regulating compositions |
| US6013009A (en) | 1996-03-12 | 2000-01-11 | Karkanen; Kip Michael | Walking/running heart rate monitoring system |
| US5677279A (en) | 1996-12-16 | 1997-10-14 | Amylin Pharmaceuticals, Inc. | Methods and compositions for treating pain with amylin or agonists thereof |
| US6307018B1 (en) | 1996-12-24 | 2001-10-23 | The Scripps Research Institute | General chemical ligation |
| ATE304864T1 (en) * | 1997-01-07 | 2005-10-15 | Amylin Pharmaceuticals Inc | USE OF EXEDINES AND THEIR ANTAGONISTS TO REDUCE FOOD INTAKE |
| US7312196B2 (en) | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| US6410511B2 (en) | 1997-01-08 | 2002-06-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| US6309360B1 (en) | 1997-03-17 | 2001-10-30 | James R. Mault | Respiratory calorimeter |
| US7101853B2 (en) * | 1997-05-06 | 2006-09-05 | Amylin Pharmaceuticals, Inc. | Method for treating or preventing gastritis using amylin or amylin agonists |
| US20040022807A1 (en) | 1998-06-05 | 2004-02-05 | Duft Bradford J | Methods for treating obesity |
| WO1998056807A1 (en) | 1997-06-13 | 1998-12-17 | Gryphon Sciences | Solid phase native chemical ligation of unprotected or n-terminal cysteine protected peptides in aqueous solution |
| EP1091440B1 (en) | 1998-05-29 | 2010-06-02 | JGC Catalysts and Chemicals Ltd. | Method of manufacturing photoelectric cell |
| US6087334A (en) | 1998-08-21 | 2000-07-11 | Amylin Pharmaceuticals, Inc. | Anti-diabetic peptides |
| JP2002527358A (en) | 1998-08-31 | 2002-08-27 | グリフォン サイエンシーズ | Lipid matrix assisted chemical ligation method and synthesis of membrane polypeptide |
| US6194006B1 (en) | 1998-12-30 | 2001-02-27 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of microparticles having a selected release profile |
| TW514510B (en) | 1999-06-11 | 2002-12-21 | Tanita Seisakusho Kk | Method and apparatus for measuring distribution of body fat |
| US6468222B1 (en) | 1999-08-02 | 2002-10-22 | Healthetech, Inc. | Metabolic calorimeter employing respiratory gas analysis |
| US6530886B1 (en) | 1999-10-08 | 2003-03-11 | Tanita Corporation | Method and apparatus for measuring subcutaneous fat using ultrasonic wave |
| US6264987B1 (en) | 2000-05-19 | 2001-07-24 | Alkermes Controlled Therapeutics Inc. Ii | Method for preparing microparticles having a selected polymer molecular weight |
| TW515705B (en) | 2000-05-31 | 2003-01-01 | Yamato Scale Co Ltd | Visceral fat meter |
| US6296842B1 (en) | 2000-08-10 | 2001-10-02 | Alkermes Controlled Therapeutics, Inc. | Process for the preparation of polymer-based sustained release compositions |
| US7118737B2 (en) | 2000-09-08 | 2006-10-10 | Amylin Pharmaceuticals, Inc. | Polymer-modified synthetic proteins |
| CA2412277A1 (en) | 2000-09-08 | 2002-03-14 | Gryphon Therapeutics, Inc. | Synthetic erythropoiesis stimulating proteins |
| US6475158B1 (en) | 2000-10-24 | 2002-11-05 | Korr Medical Technologies, Inc. | Calorimetry systems and methods |
| GB0113657D0 (en) | 2001-06-05 | 2001-07-25 | Geneprot Inc | Improved native chemical ligation with three or more components |
| FR2827599A1 (en) | 2001-07-20 | 2003-01-24 | Neuro3D | Treating central nervous system disorders, e.g. anxiety, depression, schizophrenia or pain, using new or known 2-substituted quinoline or quinoxaline derivatives having xanthenuric acid modulating action |
| US20040138412A1 (en) | 2001-09-07 | 2004-07-15 | Paolo Botti | Extended native chemical ligation |
| JP4399627B2 (en) | 2001-11-14 | 2010-01-20 | ジェネプロット インコーポレーティッド | Chemical peptide ligation with three or more components |
| DE60324387D1 (en) | 2002-01-08 | 2008-12-11 | Amylin Pharmaceuticals Inc | USE OF AMYLIN, AMYLINANALOGA AND AMYLIN DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA AND HYPERTRIGLYCERIDEMIA |
| TWI281914B (en) * | 2002-05-29 | 2007-06-01 | Glaxo Group Ltd | Compounds |
| ATE316096T1 (en) | 2002-06-10 | 2006-02-15 | Geneprot Inc | METHOD FOR CARBOXY GROUP PROTECTION OF C-TERMINAL AMINO ACIDS DURING CHEMICAL LINKAGE OF OLIGOPEPTIDES |
| WO2004048547A2 (en) | 2002-11-26 | 2004-06-10 | The Board Of Trustees Of The Leland Stanford Junior University | Intermedin and its uses |
| AU2003300416A1 (en) | 2002-12-30 | 2004-07-29 | Gryphon Therapeutics, Inc. | Multiplex polymer ligation |
| US20040197287A1 (en) * | 2003-04-04 | 2004-10-07 | The Procter & Gamble Company | Personal care composition containing an antidandruff component and a nonionic surfactant |
| WO2004105685A2 (en) | 2003-05-22 | 2004-12-09 | Gryphon Therapeutics, Inc. | Displaceable linker solid phase chemical ligation |
| DE602005021858D1 (en) | 2004-02-11 | 2010-07-29 | Amylin Pharmaceuticals Inc | PEPTIDES OF THE AMYLIN FAMILY, PROCESS FOR THEIR PREPARATION AND USE |
| US7399744B2 (en) | 2004-03-04 | 2008-07-15 | Amylin Pharmaceuticals, Inc. | Methods for affecting body composition |
| CN101035806A (en) | 2004-10-08 | 2007-09-12 | 安米林药品公司 | Amylin family polypeptide-6 (AFP-6) analogs and methods of making and using them |
| WO2006105345A2 (en) | 2005-03-31 | 2006-10-05 | Amylin Pharmaceuticals, Inc. | Compositions and methods for the control, prevention, and treatment of obesity and eating disorders |
-
2006
- 2006-03-31 WO PCT/US2006/011768 patent/WO2006105345A2/en active Application Filing
- 2006-03-31 JP JP2008504396A patent/JP5415067B2/en not_active Expired - Fee Related
- 2006-03-31 MX MX2007012236A patent/MX2007012236A/en active IP Right Grant
- 2006-03-31 AU AU2006230420A patent/AU2006230420B2/en not_active Ceased
- 2006-03-31 EP EP06749305A patent/EP1888094B1/en active Active
- 2006-03-31 CN CN2011102204917A patent/CN102343084A/en active Pending
- 2006-03-31 AU AU2006230602A patent/AU2006230602B2/en not_active Ceased
- 2006-03-31 NZ NZ561936A patent/NZ561936A/en not_active IP Right Cessation
- 2006-03-31 CN CN2006800192236A patent/CN101189021B/en not_active Expired - Fee Related
- 2006-03-31 AT AT06749305T patent/ATE439140T1/en active
- 2006-03-31 BR BRPI0609595A patent/BRPI0609595A8/en not_active IP Right Cessation
- 2006-03-31 US US11/910,214 patent/US7879794B2/en not_active Expired - Fee Related
- 2006-03-31 EP EP10008998.6A patent/EP2258382A3/en not_active Withdrawn
- 2006-03-31 KR KR1020077025124A patent/KR20080003849A/en active IP Right Grant
- 2006-03-31 DE DE602006008456T patent/DE602006008456D1/en active Active
- 2006-03-31 CA CA002602261A patent/CA2602261A1/en not_active Abandoned
- 2006-03-31 EP EP10008733A patent/EP2248527A3/en not_active Withdrawn
- 2006-03-31 KR KR1020077025152A patent/KR101383493B1/en not_active IP Right Cessation
- 2006-03-31 ES ES06749305T patent/ES2330671T3/en active Active
- 2006-03-31 BR BRPI0606466-3A patent/BRPI0606466A2/en not_active IP Right Cessation
- 2006-03-31 JP JP2008504532A patent/JP5114381B2/en not_active Expired - Fee Related
- 2006-03-31 AT AT06740117T patent/ATE480255T1/en not_active IP Right Cessation
- 2006-03-31 EP EP09009392.3A patent/EP2135617A3/en not_active Withdrawn
- 2006-03-31 US US11/910,206 patent/US7671023B2/en not_active Expired - Fee Related
- 2006-03-31 MX MX2007012237A patent/MX2007012237A/en active IP Right Grant
- 2006-03-31 NZ NZ578299A patent/NZ578299A/en not_active IP Right Cessation
- 2006-03-31 DK DK06749305T patent/DK1888094T3/en active
- 2006-03-31 WO PCT/US2006/012601 patent/WO2006105527A2/en active Application Filing
- 2006-03-31 CA CA002602584A patent/CA2602584A1/en not_active Abandoned
- 2006-03-31 DE DE602006016760T patent/DE602006016760D1/en active Active
- 2006-03-31 EP EP06740117A patent/EP1871403B1/en active Active
- 2006-03-31 NZ NZ578298A patent/NZ578298A/en not_active IP Right Cessation
- 2006-03-31 EA EA200702126A patent/EA013121B1/en not_active IP Right Cessation
- 2006-03-31 KR KR1020137025456A patent/KR20130122983A/en not_active Application Discontinuation
- 2006-10-04 CN CNA2006800541222A patent/CN101415435A/en active Pending
-
2007
- 2007-09-24 IL IL186200A patent/IL186200A/en not_active IP Right Cessation
-
2009
- 2009-12-18 US US12/641,733 patent/US20100125054A1/en not_active Abandoned
-
2010
- 2010-12-09 US US12/964,516 patent/US8278267B2/en not_active Expired - Fee Related
-
2011
- 2011-05-20 US US13/112,290 patent/US8389477B2/en not_active Expired - Fee Related
-
2012
- 2012-09-28 US US13/631,577 patent/US20130225485A1/en not_active Abandoned
-
2013
- 2013-02-26 US US13/777,149 patent/US20130184213A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008534627A5 (en) | ||
| JP2019031502A5 (en) | ||
| Bourne et al. | Sleep disruption in critically ill patients–pharmacological considerations | |
| JP2010535252A5 (en) | ||
| JP2014517050A5 (en) | ||
| JP2008538582A (en) | Novel therapeutic combinations for the treatment or prevention of psychotic disorders | |
| JP2010529118A5 (en) | ||
| JP2007523168A5 (en) | ||
| JP2018501299A5 (en) | ||
| DE602005026007D1 (en) | OPIOIDES FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE LUNG DISEASE (COPD) | |
| JP2005506370A5 (en) | ||
| JP2005500357A5 (en) | ||
| NO20092231L (en) | Arylvinyl azacycloalkane compounds and processes for their preparation and use thereof | |
| CN100586945C (en) | Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists | |
| HRP20120144T1 (en) | Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity | |
| ATE451368T1 (en) | AZABICYCLIC COMPOUNDS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISEASES | |
| JP2007516193A5 (en) | ||
| JP2011507861A5 (en) | ||
| MX2010009643A (en) | 2-aminoquinoline derivatives as 5-ht ( 5a) receptor antagonists. | |
| JP2008519056A5 (en) | ||
| CL2007002133A1 (en) | COMPOUNDS DERIVED FROM CARBOXAMIDE CHROME OR THIOCHROMEN, DOPAMINERGIC LIGANDS D3; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF A DISEASE OR A NEUROLOGICAL OR PSYCHIATRIC DISORDER AS SICK | |
| JP2022180531A5 (en) | ||
| JP2007509960A5 (en) | ||
| JP2011524898A5 (en) | ||
| FR2918282B1 (en) | MEDICINE FOR THE TREATMENT OF PARKINSON'S DISEASE |